|
Oncology Competitive Intelligence Leaders
News
Oncology Experts: A Central Source for Insights and Strategic Analysis
Featured Story
September 30, 2026
The 2026 ESMO LBA Landscape: Visualized
Which mechanisms are commanding the late-breaker spotlight this year? Our analysts crunched the numbers across all LBAs: ADCs lead the field — nearly a third of all LBA drugs, spanning NSCLC, breast, ovarian, and beyond.
- SCLC
- Lung
- ADCs
- +4
No results. Try clearing a filter or searching for something else.